Received May 14, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | W013388 | OT |
interrupted administration schedule for GARDASIL 9. HCP stated that a 14 year old male patient had received the first dose of GARDASIL 9 at age 11, on 02/21/2023 and has not received the second dose yet.; No additional AE; This spontaneous report was received from other health professional, concerning to A 14-year-old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 21-Feb-2023, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (lot #W013388 has been verified to be valid, expiration date reported and confirmed as 16-Dec-2024) 0.5 mL administered by Intramuscular route, as prophylaxis. The patient had not received the second dose yet (Inappropriate schedule of product administration). No symptoms were reported. No additional adverse event (No adverse event).